Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2026-04-20 Sale | 2026-04-22 6:27 pm | Roivant Sciences Ltd. | ROIV | Venker Eric President & Immunovant CEO | 200,000 | $29.59 | $5,918,000 | 6,292,380 (Direct) | View |
| 2026-04-16 Sale | 2026-04-20 6:27 pm | Roivant Sciences Ltd. | ROIV | Gline Matthew CEO | 289,774 | $29.16 | $8,449,810 | 16,736,116 (Direct) | View |
| 2026-04-08 Sale | 2026-04-10 6:00 pm | Roivant Sciences Ltd. | ROIV | Humes Jennifer Chief Accounting Officer | 13,538 | $28.37 | $384,073 | 84,191 (Direct) | View |
| 2026-03-26 Sale | 2026-03-30 9:01 pm | Roivant Sciences Ltd. | ROIV | Fitzgerald Meghan Director | 70,000 | $27.45 | $1,921,500 | 91,541 (Direct) | View |
| 2026-03-17 Sale | 2026-03-19 6:36 pm | Roivant Sciences Ltd. | ROIV | Venker Eric President & Immunovant CEO | 200,000 | $28.24 | $5,648,000 | 6,492,380 (Direct) | View |
| 2026-03-16 Sale | 2026-03-18 6:23 pm | Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director | 41,861 | $28.68 | $1,200,573 | 15,804 (Direct) | View |
| 2026-02-19 Sale | 2026-02-23 8:40 pm | Roivant Sciences Ltd. | ROIV | Torti Frank President and Vant Chair | 3,000,000 | $27.35 | $82,039,460 | 25,002,489 (Direct) | View |
| 2026-02-13 Sale | 2026-02-18 5:57 pm | Roivant Sciences Ltd. | ROIV | Venker Eric President & Immunovant CEO | 200,000 | $26.49 | $5,298,000 | 6,699,431 (Direct) | View |
| 2026-02-11 Sale | 2026-02-13 9:02 pm | Roivant Sciences Ltd. | ROIV | MANCHESTER KEITH S Director | 1,225,784 | $26.64 | $32,658,518 | 15,127,329 (Indirect) | View |
| 2026-02-11 Sale | 2026-02-13 9:00 pm | Roivant Sciences Ltd. | ROIV | Gold Daniel Allen Director | 1,225,784 | $26.64 | $32,658,518 | 15,127,329 (Indirect) | View |
| 2026-02-11 Sale | 2026-02-13 8:45 pm | Roivant Sciences Ltd. | ROIV | QVT Financial LP Director by Deputization Director | 1,225,784 | $26.64 | $32,658,518 | 15,127,329 (Indirect) | View |
| 2026-02-09 Sale | 2026-02-11 5:53 pm | Roivant Sciences Ltd. | ROIV | Sukhatme Mayukh President & CIO | 339,441 | $26.47 | $8,985,003 | 19,148,664 (Direct) | View |
| 2026-01-12 Sale | 2026-01-14 9:00 pm | Roivant Sciences Ltd. | ROIV | Venker Eric President & Immunovant CEO | 200,000 | $21.92 | $4,384,000 | 6,899,431 (Direct) | View |
| 2025-12-29 Sale | 2025-12-31 9:00 pm | Roivant Sciences Ltd. | ROIV | Sukhatme Mayukh President & CIO | 1,330,868 | $21.72 | $28,902,500 | 21,355,472 (Direct) | View |
| 2025-12-23 Sale | 2025-12-29 9:00 pm | Roivant Sciences Ltd. | ROIV | Pulik Richard CFO | 406,731 | $22.43 | $9,122,307 | 979,413 (Direct) | View |
| 2025-12-23 Sale | 2025-12-29 9:00 pm | Roivant Sciences Ltd. | ROIV | Venker Eric President & Immunovant CEO | 275,000 | $22.47 | $6,179,750 | 12,662,113 (Direct) | View |
| 2025-12-17 Sale | 2025-12-19 9:04 pm | Roivant Sciences Ltd. | ROIV | Sukhatme Mayukh President & CIO | 26,831 | $23.09 | $619,528 | 20,173,427 (Direct) | View |
| 2025-12-16 Sale | 2025-12-18 7:54 pm | Roivant Sciences Ltd. | ROIV | Gold Daniel Allen Director | 1,694,614 | $23.05 | $39,065,213 | 16,353,113 (Indirect) | View |
| 2025-12-16 Sale | 2025-12-18 7:52 pm | Roivant Sciences Ltd. | ROIV | MANCHESTER KEITH S Director | 1,694,614 | $23.05 | $39,065,213 | 16,353,113 (Indirect) | View |
| 2025-12-16 Sale | 2025-12-18 7:41 pm | Roivant Sciences Ltd. | ROIV | QVT Financial LP Director by Deputization Director | 1,694,614 | $23.05 | $39,065,213 | 16,353,113 (Indirect) | View |
| 2025-12-15 Sale | 2025-12-17 9:00 pm | Roivant Sciences Ltd. | ROIV | Gline Matthew CEO | 1,740,000 | $21.68 | $37,723,200 | 19,417,740 (Direct) | View |
| 2025-12-11 Sale | 2025-12-15 9:34 pm | Roivant Sciences Ltd. | ROIV | Ramaswamy Vivek 10% Owner | 3,103,745 | $21.89 | $67,942,352 | 124,071,047 (Indirect Direct) | View |
| 2025-12-12 Purchase | 2025-12-12 5:17 pm | Immunovant Inc. | IMVT | Roivant Sciences Ltd. Director 10% Owner | 16,666,666 | $21 | $349,999,986 | 113,317,007 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2026-04-20 Exercise | 2026-04-22 6:27 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Venker Eric President & Immunovant CEO | 200,000 | $3.85 | 6,292,380 (Direct) | View |
| 2026-04-20 Exercise | 2026-04-22 6:27 pm | N/A 2032-04-19 | Roivant Sciences Ltd. | ROIV | Venker Eric President & Immunovant CEO | 200,000 | $0 | 6,292,380 (Direct) | View |
| 2026-04-20 Option Award | 2026-04-22 6:26 pm | N/A 2036-04-19 | Roivant Sciences Ltd. | ROIV | Pulik Richard CFO | 144,670 | $0 | 381,537 (Direct) | View |
| 2026-04-20 Option Award | 2026-04-22 6:26 pm | N/A 2036-04-19 | Roivant Sciences Ltd. | ROIV | Humes Jennifer Chief Accounting Officer | 56,330 | $0 | 140,521 (Direct) | View |
| 2026-04-17 Tax Withholding | 2026-04-21 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Oren Ilan Director | 95 | $29.83 | 120,229 (Direct) | View |
| 2026-04-17 Option Award | 2026-04-21 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Oren Ilan Director | 896 | $0 | 120,229 (Direct) | View |
| 2026-04-17 Option Award | 2026-04-21 6:34 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director | 670 | $0 | 16,474 (Direct) | View |
| 2026-04-17 Tax Withholding | 2026-04-21 6:32 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | MOMTAZEE JAMES C Director | 94 | $29.83 | 109,405 (Direct) | View |
| 2026-04-17 Option Award | 2026-04-21 6:32 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | MOMTAZEE JAMES C Director | 469 | $0 | 109,405 (Direct) | View |
| 2026-03-31 Tax Withholding | 2026-04-02 7:14 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Torti Frank President and Vant Chair | 160,035 | $27.7 | 13,576,512 (Direct) | View |
| 2026-03-30 Exercise | 2026-04-01 7:20 pm | N/A 2026-03-31 | Roivant Sciences Ltd. | ROIV | Gline Matthew CEO | 2,178,150 | $11.5 | 17,025,890 (Direct) | View |
| 2026-03-30 Tax Withholding | 2026-04-01 7:20 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Gline Matthew CEO | 53,826 | $26.41 | 17,025,890 (Direct) | View |
| 2026-03-31 Tax Withholding | 2026-04-01 7:20 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Gline Matthew CEO | 304,684 | $27.7 | 17,025,890 (Direct) | View |
| 2026-03-30 Exercise | 2026-04-01 7:20 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Gline Matthew CEO | 97,319 | $0 | 17,025,890 (Direct) | View |
| 2026-03-30 Exercise | 2026-04-01 7:19 pm | N/A 2026-03-31 | Roivant Sciences Ltd. | ROIV | Sukhatme Mayukh President & CIO | 1,306,889 | $11.5 | 18,677,617 (Direct) | View |
| 2026-03-30 Tax Withholding | 2026-04-01 7:19 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Sukhatme Mayukh President & CIO | 29,809 | $26.41 | 18,677,617 (Direct) | View |
| 2026-03-31 Tax Withholding | 2026-04-01 7:19 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Sukhatme Mayukh President & CIO | 187,512 | $27.7 | 18,677,617 (Direct) | View |
| 2026-03-30 Exercise | 2026-04-01 7:19 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Sukhatme Mayukh President & CIO | 58,391 | $0 | 18,677,617 (Direct) | View |
| 2026-03-26 Exercise | 2026-03-30 9:01 pm | N/A 2033-04-19 | Roivant Sciences Ltd. | ROIV | Fitzgerald Meghan Director | 70,000 | $0 | 91,541 (Direct) | View |
| 2026-03-26 Exercise | 2026-03-30 9:01 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Fitzgerald Meghan Director | 70,000 | $8.8 | 91,541 (Direct) | View |
| 2026-03-20 Tax Withholding | 2026-03-24 7:08 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Pulik Richard CFO | 1,546 | $27.7 | 236,867 (Direct) | View |
| 2026-03-20 Tax Withholding | 2026-03-24 7:07 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Humes Jennifer Chief Accounting Officer | 14,526 | $27.7 | 97,729 (Direct) | View |
| 2026-03-17 Exercise | 2026-03-19 6:36 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Venker Eric President & Immunovant CEO | 200,000 | $3.85 | 6,492,380 (Direct) | View |
| 2026-03-17 Exercise | 2026-03-19 6:36 pm | N/A 2032-04-19 | Roivant Sciences Ltd. | ROIV | Venker Eric President & Immunovant CEO | 200,000 | $0 | 6,492,380 (Direct) | View |
| 2026-02-20 Tax Withholding | 2026-02-24 6:43 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Pulik Richard CFO | 1,000 | $27.15 | 238,413 (Direct) | View |
| 2026-02-20 Tax Withholding | 2026-02-24 6:43 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Venker Eric President & Immunovant CEO | 7,051 | $27.15 | 1,647,546 (Direct) | View |
| 2026-02-19 Exercise | 2026-02-23 8:40 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Torti Frank President and Vant Chair | 3,000,000 | $3.85 | 25,002,489 (Direct) | View |
| 2026-02-19 Exercise | 2026-02-23 8:40 pm | N/A 2032-04-19 | Roivant Sciences Ltd. | ROIV | Torti Frank President and Vant Chair | 3,000,000 | $0 | 25,002,489 (Direct) | View |
| 2026-02-13 Exercise | 2026-02-18 5:57 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Venker Eric President & Immunovant CEO | 200,000 | $3.85 | 6,699,431 (Direct) | View |
| 2026-02-13 Exercise | 2026-02-18 5:57 pm | N/A 2032-04-19 | Roivant Sciences Ltd. | ROIV | Venker Eric President & Immunovant CEO | 200,000 | $0 | 6,699,431 (Direct) | View |
| 2026-02-09 Exercise | 2026-02-11 5:53 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Sukhatme Mayukh President & CIO | 651,558 | $12.68 | 19,148,664 (Direct) | View |
| 2026-02-09 Exercise | 2026-02-11 5:53 pm | N/A 2026-03-31 | Roivant Sciences Ltd. | ROIV | Sukhatme Mayukh President & CIO | 651,558 | $0 | 19,148,664 (Direct) | View |
| 2026-02-09 Other | 2026-02-11 5:53 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Sukhatme Mayukh President & CIO | 312,117 | $26.47 | 19,148,664 (Direct) | View |
| 2026-01-20 Option Award | 2026-01-22 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | MOMTAZEE JAMES C Director | 609 | $0 | 109,030 (Direct) | View |
| 2026-01-20 Tax Withholding | 2026-01-22 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | MOMTAZEE JAMES C Director | 122 | $22.98 | 109,030 (Direct) | View |
| 2026-01-20 Option Award | 2026-01-22 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Oren Ilan Director | 1,164 | $0 | 119,428 (Direct) | View |
| 2026-01-20 Tax Withholding | 2026-01-22 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Oren Ilan Director | 124 | $22.98 | 119,428 (Direct) | View |
| 2026-01-20 Option Award | 2026-01-22 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director | 815 | $0 | 57,665 (Direct) | View |
| 2026-01-20 Tax Withholding | 2026-01-22 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director | 54 | $22.98 | 57,665 (Direct) | View |
| 2026-01-12 Exercise | 2026-01-14 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Venker Eric President & Immunovant CEO | 200,000 | $3.85 | 6,899,431 (Direct) | View |
| 2026-01-12 Exercise | 2026-01-14 9:00 pm | N/A 2032-04-19 | Roivant Sciences Ltd. | ROIV | Venker Eric President & Immunovant CEO | 200,000 | $0 | 6,899,431 (Direct) | View |
| 2025-12-31 Other | 2025-12-31 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Sukhatme Mayukh President & CIO | 1,430,882 | $21.71 | 21,355,472 (Direct) | View |
| 2025-12-29 Exercise | 2025-12-31 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Sukhatme Mayukh President & CIO | 3,198,235 | $12.68 | 21,355,472 (Direct) | View |
| 2025-12-29 Exercise | 2025-12-31 9:00 pm | N/A 2026-03-31 | Roivant Sciences Ltd. | ROIV | Sukhatme Mayukh President & CIO | 3,198,235 | $0 | 21,355,472 (Direct) | View |
| 2025-12-29 Other | 2025-12-31 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Sukhatme Mayukh President & CIO | 436,485 | $21.74 | 21,355,472 (Direct) | View |
| 2025-12-24 Other | 2025-12-29 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Torti Frank President and Vant Chair | 64,891 | $22.47 | 13,801,438 (Direct) | View |
| 2025-12-24 Gift | 2025-12-29 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Torti Frank President and Vant Chair | 110,489 | $0 | 13,801,438 (Direct) | View |
| 2025-12-23 Option Award | 2025-12-29 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Torti Frank President and Vant Chair | 175,380 | $22.45 | 13,801,438 (Direct) | View |
| 2025-12-23 Exercise | 2025-12-29 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Pulik Richard CFO | 260,000 | $3.85 | 979,413 (Direct) | View |
| 2025-12-23 Exercise | 2025-12-29 9:00 pm | N/A 2032-04-19 | Roivant Sciences Ltd. | ROIV | Pulik Richard CFO | 260,000 | $0 | 979,413 (Direct) | View |
| 2025-12-23 Exercise | 2025-12-29 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Venker Eric President & Immunovant CEO | 431,689 | $3.85 | 12,662,113 (Direct) | View |
| 2025-12-23 Exercise | 2025-12-29 9:00 pm | N/A 2032-04-19 | Roivant Sciences Ltd. | ROIV | Venker Eric President & Immunovant CEO | 431,689 | $0 | 12,662,113 (Direct) | View |
| 2025-12-20 Tax Withholding | 2025-12-23 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Pulik Richard CFO | 2,129 | $22.41 | 386,144 (Direct) | View |
| 2025-12-17 Exercise | 2025-12-19 9:04 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Sukhatme Mayukh President & CIO | 59,513 | $12.68 | 20,173,427 (Direct) | View |
| 2025-12-17 Exercise | 2025-12-19 9:04 pm | N/A 2026-03-31 | Roivant Sciences Ltd. | ROIV | Sukhatme Mayukh President & CIO | 59,513 | $0 | 20,173,427 (Direct) | View |
| 2025-12-17 Other | 2025-12-19 9:04 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Sukhatme Mayukh President & CIO | 32,682 | $23.09 | 20,173,427 (Direct) | View |
| 2025-12-15 Exercise | 2025-12-17 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Gline Matthew CEO | 3,636,563 | $12.68 | 19,417,740 (Direct) | View |
| 2025-12-15 Exercise | 2025-12-17 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Gline Matthew CEO | 234,096 | $4.06 | 19,417,740 (Direct) | View |
| 2025-12-15 Other | 2025-12-17 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Gline Matthew CEO | 2,130,659 | $21.68 | 19,417,740 (Direct) | View |
| 2025-12-15 Exercise | 2025-12-17 9:00 pm | N/A 2026-04-19 | Roivant Sciences Ltd. | ROIV | Gline Matthew CEO | 3,870,659 | $0 | 19,417,740 (Direct) | View |
| 2025-12-15 Other | 2025-12-15 9:34 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Ramaswamy Vivek 10% Owner | 478,708 | $22.05 | 124,071,047 (Direct) | View |
| 2025-12-11 Exercise | 2025-12-15 9:34 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Ramaswamy Vivek 10% Owner | 7,374,868 | $12.68 | 124,071,047 (Direct) | View |
| 2025-12-12 Other | 2025-12-15 9:34 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Ramaswamy Vivek 10% Owner | 2,696,866 | $21.96 | 124,071,047 (Direct) | View |
| 2025-12-11 Exercise | 2025-12-15 9:34 pm | N/A 2026-03-31 | Roivant Sciences Ltd. | ROIV | Ramaswamy Vivek 10% Owner | 7,374,868 | $0 | 124,071,047 (Direct) | View |
| 2025-12-11 Other | 2025-12-15 9:34 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Ramaswamy Vivek 10% Owner | 1,095,550 | $21.64 | 124,071,047 (Direct) | View |